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Restaging patients with N2 (stage IIIa)
non–small cell lung cancer after
neoadjuvant chemoradiotherapy: A
closer look at redo mediastinoscopy
To the Editor:
On the basis of the data obtained by the
analysis of 93 locally advanced cases of non–
small cell lung cancer clinically restaged after
induction therapy, Cerfolio and coworkers1
conclude that when repeat positron emission
tomography (PET)/computed tomography
(CT) is adopted either in the staging or
restaging process, the percentage decrease
in maximum standardized uptake value
(maxSUV) of the primary tumor and in-
volved lymph nodes is predictive of pathol-
ogy, but pathologic assessment is still re-
quired because persistently high maxSUV
“does not equate to residual cancer.” We
commend the authors for their valuable
study. Along the line of discussion, Cer-
folio and coworkers state that “repeat
mediastinoscopy often is inaccurate and
potentially dangerous, especially after
chest irradiation” and that endoscopic
ultrasonography– guided fine-needle as-
piration (EUS-FNA) biopsy, despite be-
ing more precise and accurate, is “avail-
able only in few centers.” We would like
to amicably address the authors on this
point on the basis of our own personal
experience and confidence with redo me-
diastinoscopy. Pathologic reassessment
of the mediastinum is strongly advisable
in the setting of induction therapy for
locally advanced non–small cell lung
cancer because persistent N2 disease her-
alds a poor prognosis.
Shortly after the introduction of me-
diastinoscopy, redo procedures were con-
sidered to be technically impossible be-
Figure 1. Vascular damage to saphenous vein harvested for coronary artery bypass
grafting. Representative micrographs are shown of conventional (CONV) and no-touch
(NT) preparations of the same vein from a patient undergoing bypass grafting. The top
panels show the general structural differences where the adventitia is removed from the
conventional vein segments and, as a result of saline distention, the intimal folds seen
in the “no-touch” vein are absent and the vessel wall thickness is reduced (elastic-van
Gieson staining). The middle panels indicate a continuous lining of endothelial cells
(CD31 immunostaining) in a “no-touch” vein segment, whereas there are regions of
endothelial denudation in the conventional sample (arrow). The bottom panels show
ultrastructural changes to the vasa vasorum at the adventitial/medial border where a
microvessel is contracted and there is clumping of red blood cells in the conventional
sample, whereas in “no-touch” veins the lumen is open. Original magnifications: top
panels 20, middle panels 100, bottom panels 3000. L, Lumen.
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cause of the scar tissue developing after
the first intervention. However, in subse-
quent years, they were shown to be tech-
nically feasible also after induction chemo-
therapy. The most recent updated series of
redo mediastinoscopy after induction che-
motherapy are summarized in Table 12-5
and compared with the overall results of
restaging by means of PET/CT in the study
of Cerfolio and coworkers.1 The latter data
were extracted from Figure 2 and not re-
ported as such by the authors. Published
mortality and morbidity rates of redo me-
diastinoscopy are very low. Its main ad-
vantage consists of providing histologic
evidence of mediastinal downstaging in
contrast to the pure anatomic and histo-
logic data given by means of PET/CT.
Moreover, Cerfolio and coworkers advo-
cate the use of maxSUV of the primary
tumor and involved lymph nodes. In con-
trast to what its name suggests, maxSUV
is not standardized among different PET
scanners and centers, making comparison
and adoption of the proposed values by
other institutions impossible. Also, the
high cost of PET/CT is not addressed by
the authors.
The very interesting data coming from
the EUS-FNA series pave the way for
a constructive discussion. An alternative
strategy to avoid redo mediastinoscopy
consists of initial proof of mediastinal node
involvement by means of EUS-FNA, fol-
lowed by induction chemotherapy and, af-
terward, mediastinoscopy to evaluate me-
diastinal response. In this way a technically
more demanding redo mediastinoscopy can
be avoided by thoracic surgeons having no
experience with this technique. We would
appreciate the authors’ comments on these
remarks.
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Reply to the Editor:
Dr Cesario and colleagues have posed some
important and interesting questions con-
cerning the role of repeat mediastinoscopy
after induction radiotherapy. We need to
limit our comments to patients who have
had radiotherapy because that is the real
issue and not those who had chemotherapy
alone. The authors state that “pathologic
reassessment of the mediastinum is strongly
advisable,” and we, as our article clearly
outlines, agree. The table the authors show
compares a clinical staging modality, pos-
itron emission tomography (PET)/computed
tomography with a pathologic staging pro-
cedure (repeat mediastinoscopy). As we
have preached and written, pathologic stag-
ing always trumps clinical staging,1 and
thus this comparison is unjustified. Repeat
PET/computed tomography directs biop-
sies by providing targets for biopsy, as we
clearly state. The question is as follows:
What is the safest and most accurate way to
achieve rebiopsy of previously cancerous
N2 mediastinal lymph nodes after induc-
tion chemoradiotherapy? Although there is
little doubt that repeat mediastinoscopy can
be performed safely (as we have done sev-
eral times ourselves), we do not recom-
mend it on a national basis nor do we
believe it is accurate in most surgeons’
hands. The authors are biased by their own
skill and might not realize that the vast
majority of these patients are not seen by
surgeons who have their type of expertise.
If we send out the message that repeat
mediastinoscopy after radiotherapy is safe
and accurate or is “the standard of care,” I
fear the subsequent morbidity and even
mortality that might ensue. A large number
of patients in the United States with lung
cancer receive their surgical care from less-
experienced hands than those of Drs Gra-
none, Schil, and Cesario. The message
from our literature must take this fact into
account. I do not believe that repeat medi-
astinoscopy after chest irradiation is safe or
accurate in the typical center. In fact, al-
though it might be safe in select hands, the
accuracy is still in doubt. Careful analysis
of the articles referenced by the authors’
letter shows the relatively high morbidity
for mediastinoscopy for those who had ra-
diotherapy (not chemotherapy alone). Thus
TABLE 1. Results of redo mediastinoscopy after induction chemotherapy compared with results of PET/CT1-5
Author, year No. of patients IT
Morbidity
(%)
Mortality
(%)
Sensitivity
(%)
Specificity
(%)
Accuracy
(%)
Cerfolio and coworkers, 20061 (PET/CT study) 93 CT-RT 0 0 62 88 79
Pitz and coworkers, 20022 15 CT 0 0 71.4 100 87
Rami-Porta and coworkers, 20033 24 CT 0 0 83 100 91
Stamatis and coworkers, 20054 165 CT-RT 2.5 0 74 100 93
De Waele and coworkers, 20065 32 CT (26)
CT-RT (6)
3.1 0 71 100 84
IT, Induction therapy; CT-RT, chemoradiotherapy; CT, chemotherapy.
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